## Issam A Awad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7904104/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Perfusion and Permeability <scp>MRI</scp> Predicts Future Cavernous Angioma Hemorrhage and Growth. Journal of Magnetic Resonance Imaging, 2022, 55, 1440-1449.	3.4	9
2	Management of Intraventricular Hemorrhage. , 2022, , 1055-1065.e3.		0
3	Intraventricular Hemorrhage Expansion in the CLEAR III Trial: A Post Hoc Exploratory Analysis. Stroke, 2022, 53, 1847-1853.	2.0	5
4	Developmental venous anomalies are a genetic primer for cerebral cavernous malformations. , 2022, 1, 246-252.		21
5	Propranolol as therapy for cerebral cavernous malformations: a cautionary note. Journal of Translational Medicine, 2022, 20, 160.	4.4	5
6	Cerebral Microbleeds and Acute Hematoma Characteristics in the ATACH-2 and MISTIE III Trials. Neurology, 2022, 98, e1013-e1020.	1.1	5
7	Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions. Circulation Research, 2022, 130, 1204-1229.	4.5	109
8	Rapamycin in Cerebral Cavernous Malformations: What Doses to Test in Mice and Humans. ACS Pharmacology and Translational Science, 2022, 5, 266-277.	4.9	5
9	Association of Intraventricular Fibrinolysis With Clinical Outcomes in Intracerebral Hemorrhage: An Individual Participant Data Meta-Analysis. Stroke, 2022, 53, 2876-2886.	2.0	11
10	3D Deep Neural Network Segmentation of Intracerebral Hemorrhage: Development and Validation for Clinical Trials. Neuroinformatics, 2021, 19, 403-415.	2.8	31
11	Cerebrovascular Complications in Early Survivors of Civilian Penetrating Brain Injury. Neurocritical Care, 2021, 34, 918-926.	2.4	10
12	Prior antiplatelet therapy and haematoma expansion after primary intracerebral haemorrhage: an individual patient-level analysis of CLEAR III, MISTIE III and VISTA-ICH. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 364-369.	1.9	9
13	Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and STICH Trials. Neurosurgery, 2021, 88, 961-970.	1.1	24
14	Propranolol inhibits cavernous vascular malformations by $\hat{I}^21$ adrenergic receptor antagonism in animal models. Journal of Clinical Investigation, 2021, 131, .	8.2	28
15	Longitudinal transcriptomics define the stages of myeloid activation in the living human brain after intracerebral hemorrhage. Science Immunology, 2021, 6, .	11.9	31
16	Leukocyte dynamics after intracerebral hemorrhage in a living patient reveal rapid adaptations to tissue milieu. JCI Insight, 2021, 6, .	5.0	11
17	Impact of Intracranial Pressure Monitor–Guided Therapy on Neurologic Outcome After Spontaneous Nontraumatic Intracranial Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105540.	1.6	10
18	Temporal Evolution and Outcomes of Non-Traumatic Intracerebral Hemorrhage in Hospitalized Patients. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105584.	1.6	0

#	Article	IF	CITATIONS
19	PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism. Nature, 2021, 594, 271-276.	27.8	103
20	Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 2944-2956.	4.3	6
21	Abortive intussusceptive angiogenesis causes multi-cavernous vascular malformations. ELife, 2021, 10,	6.0	8
22	Cerebral Cavernous Malformation: From Mechanism to Therapy. Circulation Research, 2021, 129, 195-215.	4.5	82
23	Commentary: Feasibility and Morbidity of Magnetic Resonance Imaging-Guided Stereotactic Laser Ablation of Deep Cerebral Cavernous Malformations: A Report of 4 Cases. Neurosurgery, 2021, 89, E207-E208.	1.1	2
24	In Reply: Intracerebral Hemorrhage Volume Reduction and Timing of Intervention Versus Functional Benefit and Survival in the MISTIE III and STICH Trials. Neurosurgery, 2021, 89, E247-E248.	1.1	2
25	Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation. Journal of Clinical Investigation, 2021, 131, .	8.2	32
26	Intracranial Pressure and Cerebral Perfusion Pressure in Large Spontaneous Intracranial Hemorrhage and Impact of Minimally Invasive Surgery. Frontiers in Neurology, 2021, 12, 729831.	2.4	11
27	CSF and serum inflammatory response and association with outcomes in spontaneous intracerebral hemorrhage with intraventricular extension: an analysis of the CLEAR-III Trial. Journal of Neuroinflammation, 2021, 18, 179.	7.2	12
28	Post-Trial Enhanced Deployment and Technical Performance with the MISTIE Procedure per Lessons Learned. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105996.	1.6	3
29	Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project. Stroke, 2021, 52, 3829-3838.	2.0	6
30	COVID-19 in a Hemorrhagic Neurovascular Disease, Cerebral Cavernous Malformation. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106101.	1.6	3
31	Post-Stroke Depression in Patients with Large Spontaneous Intracerebral Hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 106082.	1.6	9
32	A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH). Neurosurgery, 2021, 88, 686-697.	1.1	17
33	Association Between Intraventricular Alteplase Use and Parenchymal Hematoma Volume in Patients With Spontaneous Intracerebral Hemorrhage and Intraventricular Hemorrhage. JAMA Network Open, 2021, 4, e2135773.	5.9	6
34	Phantom validation of quantitative susceptibility and dynamic contrastâ€enhanced permeability MR sequences across instruments and sites. Journal of Magnetic Resonance Imaging, 2020, 51, 1192-1199.	3.4	10
35	A Brain-Targeted Orally Available ROCK2 Inhibitor Benefits Mild and Aggressive Cavernous Angioma Disease. Translational Stroke Research, 2020, 11, 365-376.	4.2	22
36	Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature. World Neurosurgery, 2020, 136, 7-11.	1.3	7

#	Article	IF	CITATIONS
37	In Reply: Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery, 2020, 86, E411-E411.	1.1	4
38	A Pooled Analysis of Diffusion-Weighted Imaging Lesions in Patients With Acute Intracerebral Hemorrhage. JAMA Neurology, 2020, 77, 1390.	9.0	38
39	Novel Murine Models of Cerebral Cavernous Malformations. Angiogenesis, 2020, 23, 651-666.	7.2	36
40	Cerebral cavernous malformations are driven by ADAMTS5 proteolysis of versican. Journal of Experimental Medicine, 2020, 217, .	8.5	30
41	Thrombolysis for Evacuation of Intracerebral and Intraventricular Hemorrhage: A Guide to Surgical Protocols With Practical Lessons Learned From the MISTIE and CLEAR Trials. Operative Neurosurgery, 2020, 20, 98-108.	0.8	8
42	Antibodies in cerebral cavernous malformations react with cytoskeleton autoantigens in the lesional milieu. Journal of Autoimmunity, 2020, 113, 102469.	6.5	4
43	Permissive microbiome characterizes human subjects with a neurovascular disease cavernous angioma. Nature Communications, 2020, 11, 2659.	12.8	27
44	Role of Temporal Sequence in Treating Intracerebral Hemorrhage. Annals of Neurology, 2020, 88, 237-238.	5.3	3
45	Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation. GeroScience, 2020, 42, 1351-1363.	4.6	11
46	Primary intraventricular hemorrhage outcomes in the CLEAR III trial. International Journal of Stroke, 2020, 15, 872-880.	5.9	7
47	Cerebral Cavernous Malformation Proteins in Barrier Maintenance and Regulation. International Journal of Molecular Sciences, 2020, 21, 675.	4.1	20
48	Relationship of White Matter Lesions with Intracerebral Hemorrhage Expansion and Functional Outcome: MISTIE II and CLEAR III. Neurocritical Care, 2020, 33, 516-524.	2.4	11
49	Quantitative Susceptibility Mapping and Vessel Wall Imaging as Screening Tools to Detect Microbleed in Sentinel Headache. Journal of Clinical Medicine, 2020, 9, 979.	2.4	10
50	Stereotactic laser interstitial thermal therapy for epilepsy associated with solitary and multiple cerebral cavernous malformations. Neurosurgical Focus, 2020, 48, E12.	2.3	14
51	Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance. Journal of Neurosurgery, 2020, 134, 1-8.	1.6	8
52	Venous Thromboembolism After Intraventricular Hemorrhage: Results From the CLEAR III Trial. Neurosurgery, 2019, 84, 709-716.	1.1	8
53	Phenotypic characterization of murine models of cerebral cavernous malformations. Laboratory Investigation, 2019, 99, 319-330.	3.7	24
54	Cavernous angiomas: deconstructing a neurosurgical disease. Journal of Neurosurgery, 2019, 131, 1-13.	1.6	87

#	Article	IF	CITATIONS
55	Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations. Acta Neuropathologica Communications, 2019, 7, 132.	5.2	27
56	Surgery for intracerebral haemorrhage – Authors' reply. Lancet, The, 2019, 394, e22-e23.	13.7	0
57	Surgical Performance Determines Functional Outcome Benefit in the Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation (MISTIE) Procedure. Neurosurgery, 2019, 84, 1157-1168.	1.1	93
58	A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III). International Journal of Stroke, 2019, 14, 548-554.	5.9	19
59	Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet, The, 2019, 393, 1021-1032.	13.7	534
60	Rho Kinase Inhibition Blunts Lesion Development and Hemorrhage in Murine Models of Aggressive <i>Pdcd10/Ccm3</i> Disease. Stroke, 2019, 50, 738-744.	2.0	40
61	Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation. Science Translational Medicine, 2019, 11, .	12.4	51
62	Intracranial Hypertension and Cerebral Perfusion Pressure Insults in Adult Hypertensive Intraventricular Hemorrhage: Occurrence and Associations With Outcome. Critical Care Medicine, 2019, 47, 1125-1134.	0.9	43
63	Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial. Neurosurgery, 2019, 85, 843-853.	1.1	58
64	Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice. Blood, 2019, 133, 193-204.	1.4	60
65	The cerebral cavernous malformation disease causing gene KRIT1 participates in intestinal epithelial barrier maintenance and regulation. FASEB Journal, 2019, 33, 2132-2143.	0.5	11
66	Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH). Neurosurgery, 2019, 84, 954-964.	1.1	34
67	Comprehensive transcriptome analysis of cerebral cavernous malformation across multiple species and genotypes. JCI Insight, 2019, 4, .	5.0	40
68	Biomarkers of cavernous angioma with symptomatic hemorrhage. JCl Insight, 2019, 4, .	5.0	25
69	Research Update in Neuroscience for Neurosurgeons: a historical perspective. Journal of Neurosurgery, 2019, 131, 639-648.	1.6	1
70	Basic and Translational Research in Intracerebral Hemorrhage. Stroke, 2018, 49, 1308-1314.	2.0	41
71	Symptomatic Hemorrhagic Complications in Clot Lysis: Evaluation of Accelerated Resolution of Intraventricular Hemorrhage Phase III Clinical Trial (CLEAR III): A Posthoc Root-Cause Analysis. Neurosurgery, 2018, 83, 1260-1268.	1.1	5
72	The Incidence of Catheter Tract Hemorrhage and Catheter Placement Accuracy in the CLEAR III Trial. Neurocritical Care, 2018, 29, 23-32.	2.4	21

#	Article	IF	CITATIONS
73	Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth. Circulation Research, 2018, 122, 1716-1721.	4.5	47
74	Influence of Bleeding Pattern on Ischemic Lesions After Spontaneous Hypertensive Intracerebral Hemorrhage with Intraventricular Hemorrhage. Neurocritical Care, 2018, 29, 180-188.	2.4	13
75	Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations. Translational Stroke Research, 2018, 9, 34-43.	4.2	45
76	Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage. Journal of Magnetic Resonance Imaging, 2018, 47, 1133-1138.	3.4	23
77	Combined petrosal approach. Current Opinion in Otolaryngology and Head and Neck Surgery, 2018, 26, 293-301.	1.8	6
78	Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet, The, 2017, 389, 603-611.	13.7	364
79	Surgical Performance in Minimally Invasive Surgery Plus Recombinant Tissue Plasminogen Activator for Intracerebral Hemorrhage Evacuation Phase III Clinical Trial. Neurosurgery, 2017, 81, 860-866.	1.1	46
80	Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. Nature, 2017, 545, 305-310.	27.8	247
81	â€~Standards and guidelines for standards and guidelines': intracranial dural arteriovenous shunts as a paradigm. Journal of NeuroInterventional Surgery, 2017, 9, 429-430.	3.3	1
82	Demographic Risk Factors for Vascular Lesions as Etiology of Intraventricular Hemorrhage in Prospectively Screened Cases. Cerebrovascular Diseases, 2017, 43, 223-230.	1.7	9
83	Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations Based on Systematic Literature Review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery, 2017, 80, 665-680.	1.1	334
84	Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations. Journal of Experimental Medicine, 2017, 214, 3331-3346.	8.5	80
85	Permanent CSF shunting after intraventricular hemorrhage in the CLEAR III trial. Neurology, 2017, 89, 355-362.	1.1	29
86	Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations. Journal of Neurosurgery, 2017, 127, 102-110.	1.6	44
87	RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations. Stroke, 2017, 48, 187-194.	2.0	86
88	Cerebral cavernous malformations arise from endothelial gain of MEKK3–KLF2/4 signalling. Nature, 2016, 532, 122-126.	27.8	249
89	B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models. Journal of NeuroImmune Pharmacology, 2016, 11, 369-377.	4.1	39
90	Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial. Lancet Neurology, The, 2016, 15, 1228-1237.	10.2	292

#	Article	IF	CITATIONS
91	Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations. American Journal of Neuroradiology, 2016, 37, 1209-1215.	2.4	35
92	Micro-computed tomography in murine models of cerebral cavernous malformations as a paradigm for brain disease. Journal of Neuroscience Methods, 2016, 271, 14-24.	2.5	25
93	Peripheral plasma vitamin D and non-HDL cholesterol reflect the severity of cerebral cavernous malformation disease. Biomarkers in Medicine, 2016, 10, 255-264.	1.4	31
94	Accuracy of the ABC/2 Score for Intracerebral Hemorrhage. Stroke, 2015, 46, 2470-2476.	2.0	125
95	Vascular Permeability in Cerebral Cavernous Malformations. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1632-1639.	4.3	55
96	Bleeding and Infection With External Ventricular Drainage. Neurosurgery, 2015, 76, 291-301.	1.1	67
97	Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. Genetics in Medicine, 2015, 17, 188-196.	2.4	116
98	Dynamic Permeability and Quantitative Susceptibility. Stroke, 2014, 45, 598-601.	2.0	59
99	Guidelines for the Prevention of Stroke in Women. Stroke, 2014, 45, 1545-1588.	2.0	754
100	Evaluation of Iron Content in Human Cerebral Cavernous Malformation Using Quantitative Susceptibility Mapping. Investigative Radiology, 2014, 49, 498-504.	6.2	83
101	Spontaneous Intracerebral and Intraventricular Hemorrhage. Neurosurgery, 2014, 74, S142-S150.	1.1	45
102	A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase III Study of Clot Lysis Evaluation of Accelerated Resolution of Intraventricular Hemorrhage (CLEAR III). International Journal of Stroke, 2014, 9, 536-542.	5.9	102
103	Determinants of External Ventricular Drain Placement and Associated Outcomes in Patients with Spontaneous Intraventricular Hemorrhage. Neurocritical Care, 2014, 21, 426-434.	2.4	40
104	Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. Human Molecular Genetics, 2014, 23, 4357-4370.	2.9	117
105	Intensive Care After Elective Craniotomy: "All Politics Is Local― World Neurosurgery, 2014, 81, 64-65.	1.3	9
106	Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations. Journal of Neuroimmunology, 2014, 272, 67-75.	2.3	26
107	When Blood Tickles the Brain: Where Is the Argument?. World Neurosurgery, 2013, 79, 636-637.	1.3	1

2.0 119

#	Article	IF	CITATIONS
109	Minimally Invasive Surgery Plus Recombinant Tissue-type Plasminogen Activator for Intracerebral Hemorrhage Evacuation Decreases Perihematomal Edema. Stroke, 2013, 44, 627-634.	2.0	301
110	Resolution of Intraventricular Hemorrhage Varies by Ventricular Region and Dose of Intraventricular Thrombolytic. Stroke, 2012, 43, 1666-1668.	2.0	81
111	Ventricular Catheter Location and the Clearance of Intraventricular Hemorrhage. Neurosurgery, 2012, 70, 1258-1264.	1.1	35
112	Fasudil Decreases Lesion Burden in a Murine Model of Cerebral Cavernous Malformation Disease. Stroke, 2012, 43, 571-574.	2.0	130
113	Occurrence and impact of intracranial pressure elevation during treatment of severe intraventricular hemorrhage*. Critical Care Medicine, 2012, 40, 1601-1608.	0.9	69
114	Thrombolytic Evacuation of Intracerebral and Intraventricular Hemorrhage. Current Cardiology Reports, 2012, 14, 754-760.	2.9	16
115	Drainage Efficiency with Dual Versus Single Catheters in Severe Intraventricular Hemorrhage. Neurocritical Care, 2012, 16, 399-405.	2.4	32
116	External Ventricular Drainage for Intraventricular Hemorrhage. Current Neurology and Neuroscience Reports, 2012, 12, 24-33.	4.2	116
117	Comments. Neurosurgery, 2012, 71, 108.	1.1	0
118	A "pseudo-cavernoma―– An encapsulated hematoma of the choroid plexus. Journal of Clinical Neuroscience, 2011, 18, 846-848.	1.5	2
119	Intraventricular Hemorrhage Secondary to Intranidal Aneurysm Rupture—Successful Management by Arteriovenous Malformation Embolization Followed by Intraventricular Tissue Plasminogen Activator: Case Report. Neurosurgery, 2011, 68, E581-E586.	1.1	12
120	Magnetic Resonance Imaging Evaluation of Cerebral Cavernous Malformations With Susceptibility-Weighted Imaging. Neurosurgery, 2011, 68, 641-648.	1.1	80
121	Fatal "hypertensive―intracerebral hemorrhage associated with a cerebral cavernous angioma: case report. Acta Neurochirurgica, 2011, 153, 421-423.	1.7	4
122	Low-Dose Recombinant Tissue-Type Plasminogen Activator Enhances Clot Resolution in Brain Hemorrhage. Stroke, 2011, 42, 3009-3016.	2.0	169
123	A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease. Human Molecular Genetics, 2011, 20, 211-222.	2.9	120
124	A founder mutation in the Ashkenazi Jewish population affecting messenger RNA splicing of the CCM2 gene causes cerebral cavernous malformations. Genetics in Medicine, 2011, 13, 662-666.	2.4	12
125	Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. Journal of Experimental Medicine, 2010, 207, 881-896.	8.5	303
126	Emerging clinical imaging techniques for cerebral cavernous malformations: a systematic review. Neurosurgical Focus, 2010, 29, E6.	2.3	93

#	Article	IF	CITATIONS
127	Genomics of Human Intracranial Aneurysm Wall. Stroke, 2009, 40, 1252-1261.	2.0	101
128	Radiosurgery for angiographically occult vascular malformations. Neurosurgical Focus, 2009, 26, E16.	2.3	30
129	Immune Response in Human Cerebral Cavernous Malformations. Stroke, 2009, 40, 1659-1665.	2.0	52
130	Biology of Vascular Malformations of the Brain. Stroke, 2009, 40, e694-702.	2.0	194
131	OUTCOME PREDICTORS AND SPECTRUM OF TREATMENT ELIGIBILITY WITH PROSPECTIVE PROTOCOLIZED MANAGEMENT OF INTRACEREBRAL HEMORRHAGE. Neurosurgery, 2009, 64, 436-446.	1.1	20
132	CAVERNOUS MALFORMATIONS OF THE BASAL GANGLIA AND THALAMUS. Neurosurgery, 2009, 65, 7-19.	1.1	72
133	BRAINSTEM CAVERNOUS MALFORMATIONS. Neurosurgery, 2009, 64, E805-E818.	1.1	144
134	CEREBRAL CAVERNOUS MALFORMATIONS. Neurosurgery, 2009, 65, 138-145.	1.1	68
135	Different spectra of genomic deletions within the CCM genes between Italian and American CCM patient cohorts. Neurogenetics, 2008, 9, 25-31.	1.4	33
136	Current Updates in Perioperative Management of Intracerebral Hemorrhage. Neurosurgery Clinics of North America, 2008, 19, 401-414.	1.7	6
137	Hemorrhage From Cavernous Malformations of the Brain. Stroke, 2008, 39, 3222-3230.	2.0	230
138	ADVANCED MAGNETIC RESONANCE IMAGING OF CEREBRAL CAVERNOUS MALFORMATIONS. Neurosurgery, 2008, 63, 790-798.	1.1	46
139	Surrogate Measures of Outcome in Clinical Trials. Neurosurgery, 2008, 63, N5.	1.1	1
140	ADVANCED MAGNETIC RESONANCE IMAGING OF CEREBRAL CAVERNOUS MALFORMATIONS. Neurosurgery, 2008, 63, 782-789.	1.1	30
141	Engineering the Ideal Bypass Graft. Neurosurgery, 2008, 63, N9.	1.1	0
142	Oligoclonal immune response in cerebral cavernous malformations. Journal of Neurosurgery, 2007, 107, 1023-1026.	1.6	38
143	CONCEPTS AND HYPOTHESES. Neurosurgery, 2007, 61, 693-703.	1.1	45
144	On Lumbar Disc Herniation, SPORT and "We Told You So― Neurosurgery, 2007, 60, N6-N7.	1.1	0

Issam A Awad

#	Article	IF	CITATIONS
145	On COURAGE and lessons from the heart. Neurosurgery, 2007, 60, N8.	1.1	1
146	Current Updates in Perioperative Management of Intracerebral Hemorrhage. Neurologic Clinics, 2006, 24, 745-764.	1.8	19
147	SPECTRUM OF GENOTYPE AND CLINICAL MANIFESTATIONS IN CEREBRAL CAVERNOUS MALFORMATIONS. Neurosurgery, 2006, 59, 1278-1285.	1.1	56
148	Retrograde suction decompression of giant paraclinoid aneurysms using a No. 7 French balloon–containing guide catheter. Journal of Neurosurgery, 2006, 105, 479-481.	1.6	40
149	Neuroendovascular Interventions for Intracranial Posterior Circulation Disease via the Transradial Approach: Technical Case Report. Neurosurgery, 2005, 56, E626-E626.	1.1	62
150	Ruptured superior cerebellar artery aneurysm in a child with bilateral fibromuscular hyperplasia of the renal arteries. Journal of Neurosurgery: Pediatrics, 2005, 102, 338-341.	1.3	9
151	Biallelic Somatic and Germ LineCCM1Truncating Mutations in a Cerebral Cavernous Malformation Lesion. Stroke, 2005, 36, 872-874.	2.0	152
152	Intracranial cavernous angioma: a practical review of clinical and biological aspects. World Neurosurgery, 2005, 63, 319-328.	1.3	153
153	Unfolding knowledge on cerebral cavernous malformations. World Neurosurgery, 2005, 63, 317-318.	1.3	15
154	FDA Approves Vagal Nerve Stimulator for Treatment Resistant Depression. Neurosurgery, 2005, 57, N6-N6.	1.1	0
155	Multiple Spinal Cavernous Malformations with Atypical Phenotype after Prior Irradiation: Case Report. Neurosurgery, 2004, 55, E1435-E1439.	1.1	31
156	Pathobiology of human cerebrovascular malformations: basic mechanisms and clinical relevance. Neurosurgery, 2004, 55, 1-16; discussion 16-7.	1.1	96
157	What genes can teach us about human cerebrovascular malformations. Clinical Neurosurgery, 2004, 51, 140-52.	0.2	5
158	Mutational analysis of 206 families with cavernous malformations. Journal of Neurosurgery, 2003, 99, 38-43.	1.6	66
159	Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke. Circulation, 2003, 108, 1278-1290.	1.6	214
160	Coronary Risk Evaluation in Patients With Transient Ischemic Attack and Ischemic Stroke. Stroke, 2003, 34, 2310-2322.	2.0	137
161	Differential Gene Expression in Human Cerebrovascular Malformations. Neurosurgery, 2003, 52, 465-478.	1.1	101
162	Spine Patient Outcomes Research Trial. Journal of Neurosurgery, 2003, 98, 1150-2.	1.6	4

#	Article	IF	CITATIONS
163	Further Study of CD31 Protein and Messenger Ribonucleic Acid Expression in Human Cerebral Vascular Malformations. Neurosurgery, 2002, 50, 110-116.	1.1	11
164	Ode to meaning and relevance. Clinical Neurosurgery, 2002, 49, 7-18.	0.2	0
165	Expression of Endothelial Cell Angiogenesis Receptors in Human Cerebrovascular Malformations. Neurosurgery, 2001, 48, 359-368.	1.1	69
166	Vascular Smooth Muscle Cell Differentiation in Human Cerebral Vascular Malformations. Neurosurgery, 2001, 49, 671-680.	1.1	51
167	A Quality-of-Life Instrument for Young Hemorrhagic Stroke Patients. Stroke, 2001, 32, 687-695.	2.0	39
168	Recommendations for the Management of Intracranial Arteriovenous Malformations. Circulation, 2001, 103, 2644-2657.	1.6	141
169	Patterns of functional magnetic resonance imaging activation in association with structural lesions in the rolandic region: a classification system. Journal of Neurosurgery, 2001, 94, 946-954.	1.6	68
170	Molecular biology of vascular malformations of the brain. Japanese Journal of Neurosurgery, 2001, 10, 271.	0.0	0
171	Toward More Rational Prediction of Outcome in Patients with High-grade Subarachnoid Hemorrhage. Neurosurgery, 2000, 46, 28-36.	1.1	108
172	Ultrastructural Pathological Features of Cerebrovascular Malformations: A Preliminary Report. Neurosurgery, 2000, 46, 1454-1459.	1.1	170
173	Intraoperative endovascular treatment as an adjunct to microsurgical clipping of paraclinoid aneurysms. Journal of Neurosurgery, 2000, 93, 554-560.	1.6	45
174	Stereotactic Computed Tomographic–Guided Aspiration and Thrombolysis of Intracerebral Hematoma. Stroke, 2000, 31, 834-840.	2.0	133
175	Impact of Guglielmi detachable coils on outcomes of patients with intracranial aneurysms treated by a multidisciplinary team at a single institution. Journal of Neurosurgery, 2000, 93, 569-580.	1.6	31
176	Parenchymal Perianeurysmal Cystic Changes in the Brain: Report of Five Cases. Radiology, 2000, 215, 229-233.	7.3	21
177	Recommendations for the Management of Patients With Unruptured Intracranial Aneurysms. Circulation, 2000, 102, 2300-2308.	1.6	148
178	CASE PROBLEMS IN NEUROLOGICAL SURGERY. Neurosurgery, 1999, 45, 1216-1221.	1.1	3
179	Neonatal Galenic Arteriovenous Malformation. Neurosurgery, 1999, 44, 847-854.	1.1	8
180	Primary intracerebral hemorrhage and subarachnoid hemorrhage. Journal of Stroke and Cerebrovascular Diseases, 1999, 8, 146-150.	1.6	4

Issam A Awad

#	Article	IF	CITATIONS
181	A Comparison of the Clinical Profile of Cavernous Malformations with and without Associated Venous Malformations. Neurosurgery, 1999, 44, 41-46.	1.1	188
182	Spontaneous Angiographic Obliteration of Cerebral Arteriovenous Malformations. Neurosurgery, 1999, 44, 280-287.	1.1	150
183	Comparative localization of auditory comprehension by using functional magnetic resonance imaging and cortical stimulation. Journal of Neurosurgery, 1999, 91, 626-635.	1.6	81
184	De novo development of a cavernous malformation of the spinal cord following spinal axis radiation. Journal of Neurosurgery: Spine, 1999, 90, 234-238.	1.7	31
185	Failure of the hypotensive provocative test during temporary balloon test occlusion of the internal carotid artery to predict delayed hemodynamic ischemia after therapeutic carotid occlusion. World Neurosurgery, 1998, 50, 147-156.	1.3	93
186	Multilocus linkage identifies two new loci for a mendelian form of stroke, cerebral cavernous malformation, at 7p15-13 and 3q25.2-27. Human Molecular Genetics, 1998, 7, 1851-1858.	2.9	331
187	The Prospective Natural History of Cerebral Venous Malformations. Neurosurgery, 1998, 43, 200-201.	1.1	20
188	Endothelial Cell Culture From Human Cerebral Cavernous Malformations. Stroke, 1998, 29, 2426-2434.	2.0	36
189	Occipital Lobe Vascular Malformations: Prevalence of Visual Field Deficits and Prognosis after Therapeutic Intervention. Neurosurgery, 1998, 43, 415-421.	1.1	16
190	Intra-arterially Administered Papaverine for the Treatment of Symptomatic Cerebral Vasospasm. Neurosurgery, 1998, 42, 1265-1265.	1.1	3
191	Reporton Clinical Fellowship from the Congress of Neurological Surgeons Committeeon Education. Neurosurgery, 1998, 43, 680-680.	1.1	0
192	Paradoxical clinicoradiologic features of a cavernous dural arteriovenous malformation. Journal of Clinical Neuroscience, 1997, 4, 241-244.	1.5	1
193	Subspecialty certification. World Neurosurgery, 1997, 47, 407-409.	1.3	0
194	Cerebral Vascular Malformations Adjacent to Sensorimotor and Visual Cortex. Stroke, 1997, 28, 1130-1137.	2.0	103
195	Expression of Angiogenic Factors and Structural Proteins in Central Nervous System Vascular Malformations. Neurosurgery, 1996, 38, 915-925.	1.1	221
196	Expression of Angiogenesis Factors and Selected Vascular Wall Matrix Proteins in Intracranial Saccular Aneurysms. Neurosurgery, 1996, 39, 537-546.	1.1	81
197	A Founder Mutation as a Cause of Cerebral Cavernous Malformation in Hispanic Americans. New England Journal of Medicine, 1996, 334, 946-951.	27.0	257
198	Misdiagnosis of Symptomatic Cerebral Aneurysm. Stroke, 1996, 27, 1558-1563.	2.0	131

#	Article	IF	CITATIONS
199	Genetic Heterogeneity of Inherited Cerebral Cavernous Malformation. Neurosurgery, 1996, 38, 1265-1271.	1.1	82
200	Expression of Angiogenesis Factors and Selected Vascular Wall Matrix Proteins in Intracranial Saccular Aneurysms. Neurosurgery, 1996, 39, 537-547.	1.1	53
201	Intracranial Cavernous Malformations. Neurosurgery, 1995, 37, 591-605.	1.1	365
202	Expression of basement membrane and endothelial cell adhesion molecules in vascular malformations of the brain: Preliminary observations and working hypothesis. Neurological Research, 1995, 17, 49-58.	1.3	45
203	Intracarotid Amobarbital Procedure as a Predictor of Material-Specific Memory Change After Anterior Temporal Lobectomy. Epilepsia, 1995, 36, 857-865.	5.1	111
204	Galen's anecdote of the fallen sophist: on the certainty of science through anatomy. Journal of Neurosurgery, 1995, 83, 929-932.	1.6	14
205	lschemic stroke and intracranial multifocal cerebral arteriopathy in Williams syndrome. Journal of Pediatrics, 1995, 126, 945-948.	1.8	29
206	Sensitivity of Magnetic Resonance Diffusion-Weighted Imaging and Regional Relationship Between the Apparent Diffusion Coefficient and Cerebral Blood Flow in Rat Focal Cerebral Ischemia. Stroke, 1995, 26, 667-675.	2.0	41
207	Vascular Malformations and Epilepsy: Clinical Considerations and Basic Mechanisms. Epilepsia, 1994, 35, S30-43.	5.1	150
208	The Effect of Propofol on the Electroencephalogram of Patients with Epilepsy. Anesthesia and Analgesia, 1994, 78, 275-279.	2.2	58
209	Factors Predisposing to Clinical Disability in Patients with Cavernous Malformations of the Brain. Neurosurgery, 1993, 32, 730-736.	1.1	149
210	Mixed Vascular Malformations of the Brain. Neurosurgery, 1993, 33, 179-188.	1.1	306
211	Pathological Heterogeneity of Angiographically Occult Vascular Malformations of the Brain. Neurosurgery, 1993, 33, 547-555.	1.1	84
212	Giant Aneurysms of the Proximal Anterior Cerebral Artery. Neurosurgery, 1993, 33, 120-124.	1.1	20
213	Pathological Heterogeneity of Angiographically Occult Vascular Malformations of the Brain. Neurosurgery, 1993, 33, 547-555.	1.1	115
214	REVERSAL OF A DENSE, PERSISTENT, HOLOHEMISPERIC NEUROLOGICAL DEFICIT AFTER AN ENDARTERECTOMY OF THE CAROTID ARTERY. Neurosurgery, 1992, 30, 302-303.	1.1	0
215	Application of magnetic resonance angiography to neurosurgical practice: A critical review of 150 cases. Neurological Research, 1992, 14, 360-368.	1.3	21
216	Multiple vertebral hemangiomas with neurological signs. Journal of Neurosurgery, 1992, 76, 1025-1028.	1.6	45

#	Article	IF	CITATIONS
217	MRI-guided stereotactic placement of depth electrodes in temporal lobe epilepsy. British Journal of Neurosurgery, 1992, 6, 47-53.	0.8	21
218	Differences of In Vitro Electrophysiology of Hippocampal Neurons from Epileptic Patients with Mesiotemporal Sclerosis Versus Structural Lesions. Epilepsia, 1992, 33, 601-609.	5.1	72
219	Anterior temporal lobectomy with microsurgical resection of mesial structures: Surgical technique and results in 50 consecutive patients with intractable epilepsy. Journal of Epilepsy, 1991, 4, 127-138.	0.4	7
220	Natural history of the cavernous angioma. Journal of Neurosurgery, 1991, 75, 709-714.	1.6	861
221	Surgical Management Of Syringomyelia: A Five Year Experience In The Era Of Magnetic Resonance Imaging <sup>*</sup> . Neurological Research, 1991, 13, 3-9.	1.3	40
222	A new class of electrodes of â€~Intermediate Invasiveness': Preliminary experience with epidural pegs and foramen ovale electrodes in the mapping of seizure foci. Neurological Research, 1991, 13, 177-183.	1.3	25
223	Intracarotid Amobarbital Procedure: I. Prediction of Decreased Modalityâ€Specific Memory Scores After Temporal Lobectomy. Epilepsia, 1991, 32, 857-864.	5.1	72
224	Symptomatic Chiari Malformation in Adults: A New Classification Based on Magnetic Resonance Imaging with Clinical and Prognostic Significance. Neurosurgery, 1991, 28, 639-645.	1.1	197
225	Extent of Mesiobasal Resection Determines Outcome after Temporal Lobectomy for Intractable Complex Partial Seizures. Neurosurgery, 1991, 29, 55-61.	1.1	109
226	Reversal of a Dense, Persistent, Holohemispheric Neurological Deficit after an Endarterectomy of the Carotid Artery: Case Report. Neurosurgery, 1991, 29, 261-264.	1.1	9
227	Natural History of Recurrent Seizures After Resective Surgery for Epilepsy. Epilepsia, 1991, 32, 851-856.	5.1	71
228	Perioperative Management and Outcome after Surgical Treatment of Anterior Cerebral Artery Aneurysms. Canadian Journal of Neurological Sciences, 1991, 18, 120-125.	0.5	17
229	Intractable Epilepsy and Structural Lesions of the Brain: Mapping, Resection Strategies, and Seizure Outcome. Epilepsia, 1991, 32, 179-186.	5.1	365
230	Neurological Surgery. Journal of Clinical Neurophysiology, 1990, 7, 567.	1.7	0
231	Intraoperative Determination of the Extent of Corpus Callosotomy for Epilepsy: Two Simple Techniques. Neurosurgery, 1990, 26, 102-106.	1.1	12
232	Neurological deterioration in a patient with a spinal arteriovenous malformation following lumbar puncture. Journal of Neurosurgery, 1990, 72, 650-653.	1.6	19
233	Intracranial dural arteriovenous malformations: factors predisposing to an aggressive neurological course. Journal of Neurosurgery, 1990, 72, 839-850.	1.6	732
234	Vascular pressures and cortical blood flow in cavernous angioma of the brain. Journal of Neurosurgery, 1990, 73, 555-559.	1.6	87

#	Article	IF	CITATIONS
235	Intractable complex partial seizures associated with occult temporal lobe encephalocele and meningoangiomatosis: A case report. World Neurosurgery, 1990, 34, 318-322.	1.3	52
236	Extent of Resection in Temporal Lobectomy for Epilepsy. I. Interobserver Analysis and Correlation with Seizure Outcome. Epilepsia, 1989, 30, 756-762.	5.1	117
237	Intracranial Meningiomas in the Aged: Surgical Outcome in the Era of Computed Tomography. Neurosurgery, 1989, 24, 557-560.	1.1	104
238	Extent of Resection in Temporal Lobectomy for Epilepsy. II. Memory Changes and Neurologic Complications. Epilepsia, 1989, 30, 763-771.	5.1	137
239	Incidental Lesions Noted on Magnetic Resonance Imaging of the Brain: Prevalence and Clinical Significance in Various Age Groups. Neurosurgery, 1987, 20, 222-227.	1.1	65
240	Leptomeningeal Metastasis from Supratentorial Malignant Gliomas. Neurosurgery, 1986, 19, 247-251.	1.1	93
241	Extracranial-Intracranial Bypass Surgery: A Critical Analysis in Light of the International Cooperative Study. Neurosurgery, 1986, 19, 655-664.	1.1	112
242	Changes in intracranial stenotic lesions after extracranial-intracranial bypass surgery. Journal of Neurosurgery, 1984, 60, 771-776.	1.6	44
243	Nocardial Osteomyelitis of the Spine with Epidural Spinal Cord Compression-a Case Report. Neurosurgery, 1984, 15, 254-256.	1.1	28
244	Modification of focal cerebral ischemia by prostacyclin and indomethacin. Journal of Neurosurgery, 1983, 58, 714-719.	1.6	26
245	Traumatic postsurgical aneurysm of the intracavernous carotid artery: A delayed presentation. World Neurosurgery, 1982, 18, 54-57.	1.3	10
246	Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease. Translational Stroke Research, 0, , .	4.2	0